Cancer Biopsy Market is estimated to reach USD 79.78 billion during the forecast period

The global cancer biopsy market size was worth around USD 5.22 billion in 2023 and is predicted to grow to around USD 79.78 billion by 2032, with a compound annual growth rate of roughly 35.4% between 2024 and 2032.

A cancer biopsy is a medical test that removes a small sample of tissue or cells from the body to check for cancer. It is one of the most reliable ways doctors confirm whether abnormal cells are cancerous and identify the cancer type. During a biopsy, a doctor collects tissue from the area where cancer is suspected using a needle, surgical procedure, or other method. A specialist called a pathologist then examines the sample under a microscope. Cancer biopsy results help doctors understand the cancer’s type, grade, and other important features, supporting accurate diagnosis and treatment planning. Depending on the suspected cancer and the body area involved, doctors may recommend different biopsy methods. Early, accurate cancer diagnosis through biopsy helps healthcare professionals choose the most suitable treatment and provide better patient care.

The rising number of cancer cases worldwide, combined with the growing focus on precision oncology, is driving demand for accurate and advanced solutions in the cancer biopsy industry.

Browse the full “Cancer Biopsy Market - By Product (Kits & Consumables and Instruments), By Type (Tissue Biopsies and Liquid Biopsies), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032” Report at https://www.zionmarketresearch.com/report/cancer-biopsy-market

Market Growth Factors

• Growing cancer incidence: An aging population and lifestyle-related risk factors are increasing new cancer cases, driving demand for cancer biopsy procedures.
• Shift toward minimally invasive testing: Doctors and patients increasingly prefer needle-based and fluid-based biopsies because they cause less discomfort and support faster recovery.
• Rise of liquid biopsy: Liquid biopsy uses blood samples to detect cancer-related DNA, offering a simpler way to monitor cancer without repeated tissue sampling.

Restraints

• Cost of advanced testing: Molecular and genetic biopsy tests can be expensive, limiting access to advanced cancer testing in developing regions and smaller clinics.
• Risk of sampling errors: Tissue biopsies may sometimes miss cancer cells, leading to unclear results and the need for repeat biopsy procedures.

Cancer Biopsy Market: Report Scope

Market Segmentation

The cancer biopsy market can be segmented by product, biopsy type, cancer type, end user, and region.

Based on product, the cancer biopsy industry is divided into instruments, kits and consumables, and services. Kits and consumables hold the largest share, as every biopsy procedure requires fresh needles, collection tubes, and reagents, generating consistent repeat purchases and supporting steady demand across healthcare facilities.

Based on biopsy type, the market is classified into tissue biopsy, liquid biopsy, and image-guided biopsy. Tissue biopsy remains the most widely used method because it provides a direct, detailed view of the tumor, helping doctors confirm cancer and determine its type.

Based on cancer type, the cancer biopsy market is segregated into breast, lung, prostate, colorectal, and other cancers. Breast cancer holds a leading position due to widespread screening programs, high global incidence, and growing awareness of early cancer detection.

Based on end user, the market is categorized into hospitals, diagnostic laboratories, and specialty cancer centers. Hospitals account for the largest share because they handle most biopsy procedures, along with surgery, diagnosis, treatment, and follow-up care.

North America leads the global cancer biopsy market due to its advanced healthcare system, strong cancer research, and growing demand for early cancer diagnosis. The region has well-equipped hospitals, specialized diagnostic centers, and easy access to advanced biopsy technologies, supporting wider use of cancer biopsy procedures. The rising number of cancer cases, particularly among the aging population, is also increasing the need for accurate and timely cancer testing. In addition, higher healthcare spending allows patients and healthcare providers to adopt modern biopsy methods, including liquid biopsy and molecular testing. Strong research activities and the presence of leading medical technology companies further support market growth in the region. Favorable reimbursement policies and greater awareness of cancer screening also encourage patients to undergo diagnostic testing, helping North America maintain its leading position in the global cancer biopsy market.

Key Market Players

• Qiagen N.V.
• Hologic.Inc.
• Illumina.Inc.
• Biocept.Inc.
• ANGLE Plc
• Danaher Corporation
• Roche Holding AG
• GRAIL.Inc.
• Freenome Holdings Inc.
• Lucence Diagnostics Private Limited
• Epigenomics AG
• HelioHealth
• Genesystems.Inc.
• Natera.Inc.
• Chronix Biomedical Inc.
• Personal Genome Diagnostics Inc.
• Personalis Inc.
• Biodesix.

Recent Developments

• In June 2026, BioMark Diagnostics secured a U.S. patent allowance for a urine-based lung cancer screening technology, expanding its liquid biopsy platform beyond blood-based testing.
• In April 2026, Precede Biosciences launched Precede Bio Insight, a genome-wide liquid biopsy designed to assess tumor biology from just 1 mL of plasma, supporting cancer treatment decisions and monitoring.
• In March 2026, Myriad Genetics commercially launched Precise MRD for selected oncology practices, using circulating tumor DNA to provide earlier information about residual disease in breast cancer patients.

The global Cancer Biopsy Market is segmented as follows:

By Product

• Kits & Consumables
• Instruments

By Type

• Tissue Biopsies
• Liquid Biopsies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com